PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. PMC-403 is being explored in broader therapeutic areas, including rare vascular disease systemic capillary leak syndrome (SCLS) and kidney diseases. DAEJEON, South Korea, Oct. 15, 2024...
CooperVision to Host 4th Asia-Pacific Myopia Management Symposium in Seoul, South Korea
Held in partnership with the Korean Association of Paediatric Ophthalmology and Strabismus (KAPOS), the event will focus on advancing paediatric myopia management and shaping the future of eye health across the region. SINGAPORE, Oct. 15, 2024 /PRNewswire/ -- CooperVision, a global leader in myopia management, is proud to announce the 4th Asia-Pacific Myopia Management...
The Clinician Partners with Queensland Health for Statewide Implementation of Patient Reported Measures and Patient Safety Culture Surveys
BRISBANE, Australia, Oct. 15, 2024 /PRNewswire/ -- The Clinician has been awarded a statewide contract by Queensland Health to implement their ZEDOC platform. This platform will enhance the collection and analysis of Patient Reported Measures (PRMs) and patient safety culture (PSC) staff surveys across all Hospital and Health Services (HHS). This Off-the-Shelf (OTS) application will capture and report real-time patient...
Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations
VEVEY, Switzerland, Oct. 14, 2024 /PRNewswire/ -- Recently at Nestlé's headquarters in Vevey, Switzerland, illuma, a global super premium brand of maternal and infant nutrition under Nestlé, began its "Human Milk Oligosaccharides (HMO) Research Traceability Journey". With a focus on the most recent advancements in the field of human milk research, particularly with regard to the most sophisticated HMO formulas and...
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer
Highlights United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence (BCR), AMPLIFY. The positive results of the completed COBRA and PROPELLER trials, including the significantly higher uptake and retention in lesions compared to...
Everise Honored as Leading Disability Employer 2024 by National Organization on Disability
PLANTATION, Fla., Oct. 14, 2024 /PRNewswire/ -- Global healthcare customer experience company Everise today announced that it has been recognized by the National Organization on Disability (NOD) as a Leading Disability Employer for 2024. This prestigious honor highlights the company's ongoing commitment to creating a more inclusive and accessible workplace, where Persons...
Metabolon Launches New “Guide to Multiomics” and Accompanying Multiomics Webinar
Metabolon's new multiomics guide and webinar demystify complex omics technologies and illuminate how integrated multiomics is transforming life science research MORRISVILLE, N.C., Oct. 14, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces...
Vivance Completes Pre-Pivotal Trial of Wearable Dialysis Device; Results to be Shared at ASN Kidney Week 2024
SINGAPORE, Oct. 14, 2024 /PRNewswire/ -- Vivance, a leader in kidney care innovations, is proud to announce that the next trial phase of the wearable peritoneal dialysis (PD) device, Viva Kompact, has successfully concluded. The study was conducted at Singapore General Hospital (SGH), Singapore. The study data will be shared at American...
Tsingke Shines at Cell & Gene Therapy International 2024
BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 in Boston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovative solutions at Booth #210, engaging with researchers to support their cell and gene therapy projects. Engagement and Feedback...
US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute
TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that FDA issues Study May Proceed letter for its developing drug Pidnarulex (CX-5461) in trial entitled "Pilot Study of Pidnarulex...
